Finally, in 2019, the European Medical Agency approved sotagliflozin as adjuvant to insulin for T1D in adults, to be used in selected T1D patients with obesity and poorly controlled glycemia. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.